GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AdAlta Ltd (ASX:1AD) » Definitions » LT-Debt-to-Total-Asset

AdAlta (ASX:1AD) LT-Debt-to-Total-Asset : 0.01 (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is AdAlta LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. AdAlta's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.01.

AdAlta's long-term debt to total assets ratio increased from Dec. 2023 (0.00) to Dec. 2024 (0.01). It may suggest that AdAlta is progressively becoming more dependent on debt to grow their business.


AdAlta LT-Debt-to-Total-Asset Historical Data

The historical data trend for AdAlta's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AdAlta LT-Debt-to-Total-Asset Chart

AdAlta Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial - - 0.15 - 0.20

AdAlta Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.20 0.01

AdAlta LT-Debt-to-Total-Asset Calculation

AdAlta's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (A: Jun. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Jun. 2024 )/Total Assets (A: Jun. 2024 )
=1.18/5.779
=

AdAlta's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )/Total Assets (Q: Dec. 2024 )
=0.023/2.339
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AdAlta  (ASX:1AD) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


AdAlta LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of AdAlta's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


AdAlta Business Description

Traded in Other Exchanges
N/A
Address
Science Drive, La Trobe Institute for Molecular Science, Room 204, LIMS2, La Trobe University, Bundoora, VIC, AUS, 3086
AdAlta Ltd is engaged in drug discovery and developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The principal business of AdAlta is the discovery and development of next-generation protein and cell-based therapeutics. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases, for which current therapies are sub-optimal. Its pipeline includes Fibrosis and CAR-T cancer therapeutics.

AdAlta Headlines

No Headlines